business

Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death

Bloomberg Markets · Apr 28, 2026, 5:23 PM · Also reported by 1 other source

Erasca Inc. shares plunged as much as 55% Tuesday after the cancer-drug developer said one patient withdrew from its clinical trial and later died after suffering severe side effects related to the treatment.

Read full story on Bloomberg Markets → More top stories

Also covered by

CNBC AstraZeneca stock falls after FDA panel votes against new cancer drug

Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death

Also covered by

More in business